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Abstract 
Background: Chloroquine had been used extensively during the last five decades in Cameroon. Its decreasing clini-
cal effectiveness, supported by high proportions of clinical isolates carrying the mutant pfcrt haplotype (CVIET), led 
the health authorities to resort to amodiaquine monotherapy in 2002 and artemisinin-based combination therapy 
(ACT) in 2004 (artesunate–amodiaquine, with artemether–lumefantrine as an alternative since 2006) as the first-line 
treatment of uncomplicated malaria. The aim of the present study was to investigate whether the withdrawal of 
chloroquine was associated with a reduction in pfcrt mutant parasite population and reemergence of chloroquine-
sensitive parasites in southeastern Cameroon between 2003 and 2012.
Methods: The frequency of pfcrt haplotypes at positions 72–76 in Plasmodium falciparum isolates collected from 
individuals in 2003 and 2012 in southeastern Cameroon was determined by sequence specific oligonucleotide 
probes-enzyme linked immunosorbent assay (SSOP-ELISA).
Results: The proportions of parasites carrying the mutant haplotype CVIET and the wild-type CVMNK were 53.0 and 
28.0% in 2003, respectively. The proportion of the mutant haplotype in samples collected 9 years later decreased to 
25.3% whereas the proportion of parasites carrying the wild-type CVMNK haplotype was 53.7%.
Conclusions: Even though the proportion of chloroquine-sensitive parasites seems to be increasing in southeastern 
Cameroon, a reintroduction of chloroquine cannot be recommended at present in Cameroon. The current national 
anti-malarial drug policy should be implemented and reinforced to combat drug-resistant malaria.
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Background
Chloroquine resistance (CQR) was first reported almost 
simultaneously at the Thai–Cambodian border and in 
the Amazon basin in the late 1950s [1, 2]. It spread from 
these two foci to other regions in South America, South-
east Asia, and India during the 1960s and 1970s, and to 
East Africa in the late 1970s. Almost all sub-Saharan Afri-
can countries reported chloroquine-resistant Plasmo-
dium falciparum in the 1980s and 1990s. In Cameroon, 
the first chloroquine-resistant cases were described after 
a chemoprophylactic failure in non-immune visitors in 
1985 [3].
Chloroquine and amodiaquine were the first-line drugs 
for the treatment of uncomplicated malaria until 2002 in 
Cameroon. A series of clinical studies using the stand-
ardized World Health Organization (WHO) protocol to 
assess anti-malarial drug efficacy had shown the general 
inefficacy of chloroquine throughout the country, lead-
ing to the gradual withdrawal of chloroquine and the use 
of amodiaquine as the first-line drug for the treatment 
of uncomplicated malaria during the transition period 
between 2002 and 2004. This was followed by the adop-
tion of artemisinin-based combination therapy (ACT) in 
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2004 (artesunate–amodiaquine, with artemether–lume-
fantrine as an alternative ACT since 2006) as first-line 
treatment [4–6]. These studies showed that chloroquine 
was ineffective in central, southern, eastern, and western 
Cameroon, but had lower treatment failure rates in the 
northern Sahelian region. Sulfadoxine–pyrimethamine 
had been the second-line drug until 2004 and, since then, 
has been employed for intermittent preventive treatment 
in pregnant women. The importation of chloroquine has 
been suspended since 2002 and the drug has been with-
drawn from the official outlets by Cameroonian health 
authorities. Although chloroquine may still be available 
in the country through illicit trade, it can be presumed 
that official government measures have contributed to 
the reduction of drug pressure on the parasites due to 
chloroquine during the last decade.
Plasmodium falciparum chloroquine resistant trans-
porter (pfcrt) was identified as a CQR marker by genetic 
cross between a chloroquine-resistant clone (Dd2/Indo-
china) and a chloroquine-sensitive clone (HB3/Hondu-
ras). A single nucleotide polymorphism (SNP) encoding 
an amino acid change at codon 76 (K76T) is highly cor-
related with both in  vitro CQR and chloroquine treat-
ment failure [7]. Additional mutations in codons 72–75 
have been suggested to play a modulator role in resist-
ance or to compensate the deleterious effect of K76T [8]. 
This gene is highly polymorphic and contains eight point 
mutations M74I, N75E, K76T, A220S, Q271E, N326S, 
I356T, R371I found in the Asian and African CQR iso-
lates and in the CQR Dd2 strain [8]. The I356T mutation 
is absent in some resistant isolates. All these mutations 
localize within or near the ten predicted transmembrane 
segments and seem to be involved in hydrophilicity [8, 9]. 
Other novel mutations that have been reported include 
H97L/K, A144F/Y, L148I, L160Y, I194T, T333/S, S334N, 
C350R [9–15]. Recently, it was demonstrated that the full 
activity of PFCRT is a rigid process that requires addi-
tional mutations occurring in a specific order to prevent 
the reduction of chloroquine transport, and that a mini-
mum of two mutations are sufficient to decrease chloro-
quine transport while four mutations confer full activity 
[16]. At present, the exact process leading to chloroquine 
resistant phenotype is not fully elucidated and different 
laboratory models suggest a multigenic basis of resist-
ance. In this study the dynamics of the prevalence of 
the major pfcrt haplotypes between 2003 and 2012 were 
investigated.
Methods
Fingerprick capillary blood samples were collected 
on Isocode Stix filter papers (Schleicher and Schuell, 
Ecquevilly, France) in the clinical study carried out in 
July–August 2003 in Bertoua, Cameroon. This was part 
of a randomized study that compared the efficacy of 
amodiaquine, sulfadoxine–pyrimethamine, and amo-
diaquine–sulfadoxine–pyrimethamine combination in 
children aged less than 5  years old with uncomplicated 
malaria [5, 6]. In 2003, chloroquine (both good quality 
and poor quality medicines, including counterfeit drugs) 
was widely available throughout the country, and this 
drug had been used massively for self-medication [17]. 
Additional venous blood samples were collected into eth-
ylenediaminetetraacetic acid (EDTA)-coated tubes from 
asymptomatic individuals during a human immunodefi-
ciency virus (HIV) survey conducted in Messok in Octo-
ber 2012.
Previous molecular studies in Cameroon have shown 
that asymptomatic parasite carriers and symptomatic 
patients are infected with similar proportions of dihydro-
folate reductase (dhfr) mutant P. falciparum isolates in a 
given study site [18].
Bertoua and Messok are located in the eastern prov-
ince in southeastern Cameroon. Bertoua is the regional 
capital of the largest forest area of the country, including 
the district of Messok which occupies an area of 14,500 
hectares covered by forest between Dja and Boumba Bek 
natural reservations. Bertoua is a semi-urban area with a 
population of 218,111, and Messok is a rural area where 
most of the population of 6412 inhabitants practice 
hunting for living. The Guinea-type equatorial climate in 
Bertoua and Messok is characterized by the alternation 
between two rainy and two dry seasons. Mean annual 
rainfall varies from 1500 to 2000  mm in Bertoua and 
1600 to 1700 mm in Messok. The mean annual tempera-
ture in Bertoua and Messok fluctuates between 23 and 
25 °C.
Genomic DNA was extracted directly from blood 
using QIAamp® DNA extraction kit (Qiagen, Courta-
boeuf, France) according to the manufacturer’s instruc-
tions, or from filter papers using the boiling method 
[19]. A fragment of pfcrt spanning codons 72–76 was 
amplified by nested PCR, as described by Djimdé et  al. 
using the following primers: TCRP-1 (5′-CCGTTAAT 
AATAAATACACGCAG-3′) and TCRP-2 (5′-CGGATG 
TTACAAAACTATAGTTACC-3′) for the primary PCR 
and TCRD-1 (5′-TGTGCTCATGTGTTTAAACTT-3′) 
and TCRD-2 (5′-CAAAACTATAGTTACCAATTTT 
G-3′) [7]. The polymorphism at positions 72–76 was 
determined using sequence specific oligonucleotide 
probes-enzyme linked immunosorbent assay (SSOP-
ELISA) based technique in which SNPs are visualized in 
PCR-based ELISA as described by Alifrangis et  al. [20]. 
Proportions were compared by the Chi square test. The 
significance level was fixed at 0.05.
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Ethics
Research performed here was in accordance with the 
Declaration of Helsinki. The protocol, informed con-
sent documents, relevant supporting information, and 
all patient recruitment information were approved by 
Cameroonian national ethics committee, Cameroonian 
Ministry of Public Health, and the Ethics committee of 
Institut de Recherche pour le Développement (France). 
Written informed consent was given by all participants.
Results
A total of 179 febrile children aged less than 5 years old 
were recruited in the clinical study in Bertoua in 2003. 
The mean age (±standard deviation) was 29 ± 17 months 
(range 6–58 months old). The sex ratio was 0.97 (88 boys 
and 91 girls). The minimum required parasitaemia for 
inclusion was 2000 asexual parasites/µl of blood. Para-
sitaemia ranged from 2000 to 250,000 asexual parasites/
µl of blood. The clinical and parasitological outcome was 
published elsewhere [5, 6].
Among 101 participants of the survey conducted in 
Messok in 2012, data on age and gender were available 
for 96 and 95 individuals, respectively. The median age at 
inclusion was 36 years (interquartile range, 25–55 years 
old). There were 38 men and 57 women. Microscopic 
examination of blood smears for malaria detection was 
not performed. Individuals of all ages were included in 
the study. PCR showed that almost all included individu-
als (100 of 101, 99%) were asymptomatic carriers of P. fal-
ciparum. They were not treated with anti-malarial drugs.
The genotype of 178 isolates from Bertoua and 100 iso-
lates from Messok was analysed at amino acid positions 
72–76. Of 178 and 100 samples from Bertoua and Mes-
sok, amplified fragments were successfully obtained in 
164 (92%) and 95 (95%) samples, respectively. The results 
are summarized in Table  1. All PCR-positive samples 
were examined by SSOP-ELlSA assay. Among 164 iso-
lates collected in Bertoua in 2003, 87 (53%) carried the 
mutant CVIET haplotype, 46 (28%) carried the wild-type 
CVMNK haplotype, and 31 (19%) had mixed alleles. In 
sharp contrast, among 95 samples collected in 2012 in 
Messok, only 24 (25.3%) carried the mutant CVIET hap-
lotype, 51 (53.7%) had the wild-type CVMNK haplotype, 
and 20 (21.1%) were mixed. The alternative South Amer-
ican-type mutant haplotype SVMNT was not detected.
Discussion
The results observed in Bertoua in 2003 are consist-
ent with the high rate of chloroquine treatment failures 
observed in this region between 1999 and 2001, which 
led to the suspension of chloroquine use in the country 
[5]. The proportion of isolates with mutant pfcrt haplo-
type in Bertoua was slightly lower than that observed 
in isolates collected in Yaoundé during the same study 
period. A study conducted in Yaoundé in 2000–2001 
showed a high correlation between in  vitro response 
and pfcrt haplotype, indicating the usefulness of pfcrt 
to monitor CQR [21]. The similar proportions of P. fal-
ciparum isolates carrying the mutant pfcrt haplotype 
in Bertoua in 2003 (72%, including mixed alleles) and 
Yaoundé in 2000–2001 (70%, including mixed alleles) 
were most likely related to the widespread occurrence of 
chloroquine-resistant P. falciparum and intensive use of 
chloroquine, mainly for self-medication, during the pre-
ACT period when chloroquine was still widely available 
in Cameroon. This observation is supported by another 
study conducted in Yaoundé in 2004–2006 which 
showed that 77% of clinical isolates carried the mutant 
76T allele [22].
Although Messok is situated in the same province as 
Bertoua, there are no previous clinical or molecular data 
on P. falciparum malaria in this village. The molecular 
results of the present study showed an inverse relation-
ship between the samples collected earlier in Bertoua 
and those collected at a later date in Messok (P < 0.05). 
This inverse relationship is in agreement with high rate 
of chloroquine treatment failure observed between 1999 
and 2004 in nine sentinel sites of southern Cameroon [5]. 
The proportion of wild-type pfcrt almost doubled and 
that of mutant pfcrt halved after an interval of 9  years 
in the southeastern province of Cameroon. During this 
lapse of time, it can be safely assumed that drug pressure 
due to chloroquine declined with the suspension of drug 
importation into the country, as well as in other neigh-
boring countries in Central Africa. Moreover, despite the 
availability of chloroquine of doubtful quality through 
informal drug outlets until recent years, retrospective 
analysis of clinical records of malaria-infected patients 
enrolled in clinical studies between 2005 and 2009 in 
Yaoundé suggests that self-medication with chloroquine 
has decreased considerably, as supported by negative 
Table 1 Prevalence of  pfcrt haplotypes in  Bertoua 
and Messok, southeastern Cameroon
n number of isolates
a CVMNK (wild-type) and CVIET (mutant) haplotypes indicate amino acids at 
positions 72–76 in PfCRT. The South American-type SVMNT haplotype was not 
observed in the present study. PCR failed in 14 and 5 samples from Bertoua and 
Messok, respectively




n % n %
CVMNK 46 28.0 51 53.7
CVIET 87 53.0 24 25.3
Mixed 31 18.9 20 21.1
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Saker–Solomon’s urine test for anti-malarial drugs 
(unpublished data, Basco, personnel communication).
The reintroduction of P. falciparum isolates carrying 
wild-type pfcrt allele was first described in Malawi, and 
subsequently in other African countries as a consequence 
of the absence of drug pressure due to chloroquine 
[23–25]. The results of the present study are in agree-
ment with the earlier studies. However, the switch from 
chloroquine to amodiaquine alone and then to artesu-
nate–amodiaquine as the first-line treatment for uncom-
plicated malaria in Cameroon suggests that amodiaquine 
may not exert the same pressure as chloroquine to select 
K76T pfcrt mutant genotypes.
It is generally believed that residual chloroquine-sen-
sitive P. falciparum population expands in a predomi-
nantly chloroquine-resistant zone when drug pressure 
is relieved and outgrows the drug-resistant population 
in areas of intense transmission. Alternatively, in some 
cases, P. falciparum may have a high genetic plastic-
ity allowing this parasite to recover its primordial state 
of chloroquine-sensitive phenotype. In French Guiana, 
C350R amino acid change in pfcrt mutant isolates carry-
ing K76T substitution resulted in chloroquine-sensitive 
phenotype [24]. Although it is still unknown if other 
genetic changes elsewhere in the genome could occur 
during this process, and to what extent these changes 
can influence the transport function of PfCRT and other 
related proteins, available data suggest that reversion of 
CQR in Africa is largely due to the replacement of pfcrt 
mutant isolates by wild-type isolates [26]. A genome-
wide monitoring of African isolates is required to fol-
low future evolution of parasite populations and find 
the potential genetic changes that may possibly occur in 
wild-type and mutant pfcrt parasites.
In the present study, a significant increase in the pro-
portion of parasites carrying the wild-type pfcrt K76 hap-
lotype was observed in Messok, but the proportion of 
mutant and mixed alleles was still relatively high (25 and 
21%, respectively), possibly suggesting a slow process of 
regaining chloroquine-sensitive genotype at the parasite 
population level in areas of intense transmission. This 
observation is also compatible with a limited but con-
tinuous unauthorized use of chloroquine in the south-
eastern province. Other still unidentified local factors 
may be involved in maintaining a high proportion of pfcrt 
mutants. In a study that analysed pfcrt polymorphisms 
in clinical isolates in Yaoundé during the early years of 
ACT era (2005–2009), 71% of the isolates (81%, includ-
ing mixed alleles) still carried the mutant 76T allele [27]. 
Although the number of isolates from each study site was 
limited (n = 24 from Yaoundé and n = 21 from Bertoua), 
a general trend towards a slightly lower prevalence (56%, 
100 of 180 isolates) of mutant pfcrt CVIET haplotype 
was shown in five cities located in southern Cameroon 
in 2012, and rare mutant haplotypes (SVMNT, SVMET, 
CVMDT, CVMET, CVMNT) were found in 8% (15 of 
180) of isolates [28, 29].
It may be hypothesized that the current nationwide use 
of artesunate–amodiaquine may be contributing to the 
maintenance of mutant pfcrt haplotype. Selection of par-
asites with K76T substitution occurs with amodiaquine 
monotherapy failure [30]. However, there is some con-
tradictory evidence that similar selection of pfcrt mutants 
may not occur after artesunate–amodiaquine failure [31]. 
Further molecular analysis of recrudescent parasites after 
ACTs will be required to characterize the genotypes of 
recrudescent parasites.
Since more than a decade ago, chloroquine had been 
gradually withdrawn from the official outlets in Cam-
eroon and elsewhere in Africa. As a consequence, many 
countries have reported a decreasing trend of prevalence 
of P. falciparum isolates carrying K76T mutant pfcrt 
allele [23–25]. Although the present study is limited by 
the comparison of data from two different sites within 
the same province in Cameroon and relatively small sam-
ple size, the results are consistent with decreased drug 
pressure due to chloroquine and in agreement with simi-
lar changes reported from other African countries.
Conclusions
If the proportion of chloroquine-resistant parasites 
declines in Africa to an undetectable level of pfcrt 
mutants, a reintroduction of chloroquine in combination 
with other anti-malarial for treatment and prophylaxis 
may possibly be considered. However, at present, it is 
more important to ensure the rational use of highly effec-
tive ACTs, together with various chemopreventive strate-
gies (e.g., intermittent preventive treatment in pregnancy 
and in infants, seasonal malaria chemoprevention) and 
insecticide-impregnated bed nets, to control P. falcipa-
rum malaria. Further studies should be conducted to pre-
vent the emergence of resistance to other drugs.
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